Research into Endometrial Cancer

The main lines of research involve all the specialists concerned in the diagnosis and treatment of endometrial cancer.  

Several surgical treatment research trials for the application of the sentinel lymph node technique are underway in our hospital.  

The role of immunotherapy in combination with chemotherapy is being evaluated for systemic treatment, both in adjuvant treatment after surgery, in those patients considered to be at high risk, and for the treatment of metastatic disease.  

Drugs that have shown benefits in other gynaecological tumours, such as PARP inhibitors, are also being evaluated, both as maintenance treatment in monotherapy and in combination with immunotherapy.  

Serous endometrial tumours are characterised by mutations in a gene called TP53 and overexpression of a protein called HER2, and there are drugs under development that act on both of these therapeutic targets. 

New hormone therapy drugs are also being studied, such as selective modulators of oestrogen receptors associated or not with drugs that inhibit the division of tumour cells (cyclin inhibitors). These combinations have shown benefit in other tumours that express hormone receptors, such as breast cancer.  

Multiple lines of radiotherapy treatment research are also under development:  fractionations in postoperative brachytherapy; association of vaginal complications with the dose received; study of volumes and doses; and "in vivo" dosimetry studies for brachytherapy.